Press Release – February 20, 2015
The Medical Letter and Dymaxium Extend Their Collaboration

NEW ROCHELLE, NY - The Medical Letter is pleased to announce Dymaxium has extended their agreement to use Medical Letter content as part of the growing evidence and resources available to US health care decision makers via its AMCP eDossier System. The System continues to expand to meet the scientific requirements of payers as part of their formulary decision-making process.

The AMCP eDossier System powered by Dymaxium’s FormularyDecisions.com® platform, in partnership with the Academy of Managed Care Pharmacy (AMCP), is a centralized, secure product evaluation system that connects payers and life sciences organizations to support streamlined communication and collaboration.

The Medical Letter is one of the leading resources for unbiased and reliable drug information for physicians and pharmacists. It continues to be a part of the premium content offered to active users of the System.

"The continued availability of a full Medical Letter subscription is excellent for our System and is valuable content available for users" said Allen Lising, Managing Director, Dymaxium. "The opportunity for complete access to such a high quality reference means our users do not have to leave the System to conduct their reviews. Additionally, this provides further insights into the relevant information payers utilize to support their reimbursement decisions."

"Payers look to the reliable sources of peer-reviewed information" says Yosef Wissner-Levy, Vice President and Publisher of the Medical Letter, "and The Medical Letter is a leading and trusted resource for unbiased drug information. Our collaboration with the AMCP eDossier System has contributed to the growing number of users relying on trustworthy drug information to make their clinical decisions."

About The Medical Letter
The Medical Letter, Inc. is a non-profit organization that publishes critical appraisals of new prescription drugs and comparative reviews of previously approved drugs in its newsletter: The Medical Letter on Drugs and Therapeutics. This publication is intended specifically to meet the needs of busy healthcare professionals who want unbiased, reliable and timely drug information. The editorial process used for our publication relies on a consensus of experts to evaluate the drug facts in order to help prescribers choose the most effective drug treatment. The Medical Letter is a crucial resource for objective drug information and is completely independent of pharmaceutical industry influence. For more information call (800) 211-2769 or go to medicalletter.org.

Contact
Joanne Valentino
Director Marketing & Communications
The Medical Letter Inc.
145 Huguenot St., Suite 312
New Rochelle, NY 10801
Phone: 914.235.0500 Ext. 345
joanne@medicalletter.org

About Dymaxium Healthcare Innovations, Inc (www.dymaxium.com)
Dymaxium is a trusted market access partner differentiated by a singular focus; creating stronger connections between Payers and life sciences companies. With expertise from more than 800 unique payer-focused tools and solutions and access to over 1000 US registered payers, Dymaxium leverages these unique assets to generate data and drive insights for improved reimbursement decisions. (AMCP.edossiers.com).